By Wayne Koberstein, Executive Editor
So simple in concept — interview three CEOs of companies developing novel drugs — so challenging in execution. Who would have guessed there is such a strong correlation between novel-drug development and small-company volatility? Since my investigation began, one company replaced its CEO and changed its name, another's stock rose and fell repeatedly on news of a competing product, and a third one joined late in place of another that dropped out. All of those events are among the most common disruptions in business and communications for the microenterprises focused on unique paths of medical innovation. Thus, I stumbled upon a key insight into the lives of this industry's microinnovators: It's never easy.
By Vivian Berni, Strategic Marketing and Communications Manager, LifeConEx
When faced with environmental uncertainties, leveraging a network of trusted partners becomes a critical link in the transportation process for temperature-sensitive medicinal products.
By Ruth Olmer, Ph.D., Sebastian Selzer, and Robert Zweigerdt, Ph.D.
Human pluripotent stem cells (hPSCs) and their derivatives have gained increased importance for industrial applications in recent years.
By Victor Gill, MasterControl Inc., Senior Product Manager of Cloud Solutions
What exactly is Cloud? Or is it, The Cloud? Is it just me, or do no two people describe it the same way? As the product manager over the Cloud initiative at MasterControl I hear these kinds of questions all of the time. With all of the advertising, mixed messaging, technical jargon, and promises of grandeur, it's easy to see why so many consumers are confused. At its heart, the term The Cloud has been a powerful marketing turn of phrase that has consolidated a large mix of technologies.